CAPR, | Page 3 | RegMed Investors

utility

header_second

RegMed Investors (RMi) went exclusive on July 27th!

Your complimentary subscription to RegMed Investors’ (RMi) reporting on the stem, cell and gene therapy and RegMed sector has expired.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

It’s up to you to choose the level of content access to provide a premium experience and value - don’t wait to exhale!

I also bring fresh perspectives that yield a whole that is greater than the sum of the parts as I convey a spectrum of factors that explain outcomes, analytical principles and analysis without the encumbrance of trading, investment or I-Banking.

So, after these years of following our facts … first and fast; be part of our “inner circle” as a subscriber!

Stay with me and join our coalition and have a seat at the appreciation table!

Login Sign up now Not now

content_top

34 companies, 1 interpreter! Insight, foresight
and recommendation

0

content_middle

content_right

October 14, 2014 - 11:16am | IP & Patents
Capricor Therapeutics (OTC BB: CAPR) Acquires IP Rights to Family of Natriuretic Peptides from Medtronic (MDT) - BUY
September 18, 2014 - 9:34am | Regulatory
Capricor (CAPR) ALLSTAR PI clinical trial results

CAPR
September 8, 2014 - 3:18pm | Model Portfolio
RMi Model Portfolio and Trading List
August 18, 2014 - 2:17pm | Earnings
Capricor (CAPR) Q2/14 Earnings – Net Loss UP 20%
August 10, 2014 - 12:49pm | Clear and Present Dangers
Capricor (CAPR)

CAPR
August 3, 2014 - 10:30pm | Earnings Q2
Regenerative Medicine Earnings Scorecard - Q2/2014
July 16, 2014 - 10:02am | Research Notes
Capricor (CAPR) P1 study shows positive results
May 17, 2014 - 1:31pm | Earnings, Earnings Q1
Regenerative Medicine Earnings Scorecard - Q1/2014
May 17, 2014 - 1:27pm | Earnings
Regenerative Medicine Earnings Scorecard - FY13 by Quarter
March 28, 2014 - 2:04pm | Research Notes, Regulatory
Capricor Therapeutics (OTCQB: CAPR) enrolling for P2 ALLSTAR clinical trial- BUY
March 11, 2014 - 10:45pm | Earnings, Earnings Q4
Regenerative Medicine Earnings Scorecard - Q4/2013
February 23, 2014 - 3:20pm
CEO Compensation
February 17, 2014 - 3:57pm | Spotlight
Capricor Therapeutics, Inc., (CAPR: OTCQB) – Treating Heart Failure From a Heart to a Heart

CAPR
February 17, 2014 - 3:18pm | Executive Interview
Heart to Heart – Dr. Linda Marbán leads Capricor’s charge to change the paradigm in the treatment and prevention of heart failure.

CAPR
January 9, 2014 - 8:38am | BOD & C-Suite Updates
ISTO Technologies names George W. Dunbar, Jr, President and CEO
January 6, 2014 - 12:22pm | Research Notes
Capricor (OTCBB: CAPR) and Janssen, a J&J company ink $12.5 M collaboration and exclusive licensing agreement- +32.35%, BUY
December 17, 2013 - 9:26am | Research Notes
Capricor Therapeutics (NLTXD) P2 Portion of ALLSTAR Clinical Trial cleared to begin
November 21, 2013 - 9:12am | Research Notes
Capricor (NLXTD) and Nile Therapeutics complete reverse merger to list security
November 16, 2013 - 6:54pm | Research Notes
Skin-in-the-game

Pages

footer

© 2015 RegMed Investors (regmedinvestors.com), all rights are reserved.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry MCusker . Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of RegMed Investors (RM-i); who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other RM-i media services or reposting please email hwm@regmedinvestors.com.